RISK-BENEFIT ANALYSIS OF THERAPY IN MULTIPLE SCLEROSIS

被引：1
|
作者：
Qizilbash, N. [1 ]
Mendez, I [2 ]
Sanchez-de la Rosa, R. [3 ]
机构：
[1] Oxon Epidemiol Ltd, London, England
[2] Oxon Epidemiol Ltd, Madrid, Spain
[3] TEVA Pharma SLU, Madrid, Spain
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.469
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A317 / A318
页数：2
相关论文
共 50 条
  • [1] Risk-Benefit Analysis of Therapy in Multiple Sclerosis
    Qizilbash, Nawab
    Mendez, Ignacio
    Sanchez de la Rosa, Rainel
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 448 - 448
  • [2] Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis
    Bargiela, D.
    Bianchi, M. T.
    Westover, M. B.
    Chibnik, L. B.
    Healy, B. C.
    De Jager, P. L.
    Xia, Z.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 625 - 625
  • [3] Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis
    Bargiela, D.
    Bianchi, M. T.
    Westover, M. B.
    Chibnik, L. B.
    Healy, B. C.
    de Jager, P. L.
    Xia, Z.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 350 - 351
  • [4] Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis
    Bargiela, David
    Bianchi, Matt
    Westover, Brandon
    Healy, Brian
    De Jager, Philip
    Xia, Zongqi
    [J]. NEUROLOGY, 2017, 88
  • [5] Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis
    Bargiela, David
    Bianchi, Matthew T.
    Westover, M. Brandon
    Chibnik, Lori B.
    Healy, Brian C.
    De Jager, Philip L.
    Xia, Zongqi
    [J]. NEUROLOGY, 2017, 88 (07) : 677 - 684
  • [6] Selection of First-Line Therapy in Multiple Sclerosis Using Risk-Benefit Decision Analysis
    Bargiela, David
    Bianchi, Matt T.
    Westover, M. Brandon
    Chibnik, Lori B.
    Healy, Brian C.
    De Jager, Philip L.
    Xia, Zongqi
    [J]. ANNALS OF NEUROLOGY, 2016, 80 : S63 - S63
  • [7] Risk-benefit assessment of natalizumab therapy in multiple sclerosis patients and their treating physicians
    Kraemer, J.
    Kleiter, I.
    Meuth, S. G.
    Kasper, J.
    Koepke, S.
    Gaissmaier, W.
    Heesen, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 1014 - 1015
  • [8] Risk-benefit assessment of glatiramer acetate in multiple sclerosis
    Ziemssen, T
    Neuhaus, O
    Hohlfeld, R
    [J]. DRUG SAFETY, 2001, 24 (13) : 979 - 990
  • [9] Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis
    Tjalf Ziemssen
    Oliver Neuhaus
    Reinhard Hohlfeld
    [J]. Drug Safety, 2001, 24 : 979 - 990
  • [10] RISK-BENEFIT ANALYSIS
    ZENCEY, M
    [J]. ATLANTIC, 1979, 243 (04): : 37 - 37
12345